| Literature DB >> 23750330 |
Matthias Schulte1, Michael Sorkin, Sammy Al-Benna, Jadwiga Stupka, Tobias Hirsch, Adrien Daigeler, Marco Rainer Kesting, Hans-Ulrich Steinau, Frank Jacobsen, Lars Steinstraesser.
Abstract
Methods for human skin gene therapy requires efficient and stable introduction of genes into skin cells. Transient cutaneous gene therapy is an attractive approach in the treatment of skin diseases. The 'Achilles heel' of adenoviral gene therapy is its immunogenicity and many aspects of adenovirus induced cutaneous immune reaction still remain unanswered, particularly the role of keratinocytes. Therefore, human keratinocytes were transfected with adenoviral DNA and cytokine expression was analyzed. Moreover, adenoviral transduction of full-skin was performed ex vivo and in vivo. We observed cytokine induction after cytoplasmatic internalization of adenoviral DNA into epidermal cells. Inhibition of AIM2, NALP3, DAI or mda5 downregulated the cytokine response. Transduction of immunocompetent mice led to a detectable transgene expression for 12 days. Re-application of the vector led to a decrease in intensity and duration of transgene expression limited to 4 days and an increased cytokine expression. In contrast, immunodeficient mice showed a reduced expression of cytokines after DNA internalization. AIM2, NALP3, DAI and mda5 are essential in the induction of an innate immune response towards adenoviral DNA. This immune reaction leads to a decrease in transduction efficiency of the vector after re-application and modulation of these receptor systems stabilizes transgene expression.Entities:
Keywords: Adenovirus; Gene therapy; Innate immunity; Keratinocytes; Signal transduction; Skin
Year: 2013 PMID: 23750330 PMCID: PMC3671105 DOI: 10.1186/2193-1801-2-234
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
List of oligonucleotides used for siRNA mediated gene silencing
| Gene | Sequence |
|---|---|
| AIM2-NM_004833.1 | 5′-GCACCAUAAAGGUUAUUAA-3′ |
| NALP3-NM_004895.4 | 5′-GCUUUGUCCUCGGUACUCA-3′ |
| mda5-NM_020746.4 | 5′-GGAAUAAUCUUUACAAAAA-3′ |
| DAI-NM_030776.2 | 5′-CAAAAGAUGUGAACCGAGA-3′ |
| Control | 5′-AGGUAGUGUAAUCGCCUUG-3′ |
List of oligonucleotides used for RT-PCR (h: human; m: murine; f: forward primer; r: reverse primer; TG: target gene; AT: annealing temperature)
| Target gene (TG) | Sequence [5′-3′] | AT[°C] | ||
|---|---|---|---|---|
| Interferon α (human) - NM_024013.2 | hIFN-α1 | f: | acccacagcct ggataacag | 60 |
| r: | ctctcctcctgcatcacaca | |||
| Interferon β (human) - NM_002176.2 | hIFN-β | f: | actgcctcaaggacaggatg | 60 |
| r: | agccaggaggttctcaacaa | |||
| Interleukin 1α (human) - NM_000575.3 | hIL-1α | f: | aatgacgccctcaatcaaag | 60 |
| r: | tgggtatctcagqcatctcc | |||
| Interleukin 6 (human) - NM_000600.3 | hlL-6 | f: | caatgaggagacttgcctgg | 63 |
| r: | gcacagctctggcttgttcc | |||
| Interleukin 8 (human) - NM_000584.3 | hIL-8 | f: | tctgcagctctgtgtgaagg | 63 |
| r: | aatttctgtgttggcgcagt | |||
| Tumor necrosis factor α (human) - NM_000594.3 | hTNFα | f: | aacctcctctctgccatcaa | 62 |
| r: | ggaagacccctcccagatag | |||
| 18S ribosomal RNA (human) - X03205.1 | hl8S | f: | gaaaatgcgaatggctcattaaa | 60 |
| r: | cacagttatccaagtaggagagg | |||
| Toll-like receptor 3 (human) - NM_003265.2 | hTLR-3 | f: | agccttcaacgactgatgct | 60 |
| r: | tttccagagccgtgcta.agt | |||
| Toll-like receptor 7 (human) - NM_016562.3 | hTLR-7 | f: | ccacaaccaactqaccactg | 60 |
| r: | ccacca.gacaaaccacacag | |||
| Toll-like receptor 8 (human) - NM_138636.4 | hTLR-8 | f: | gtttcctcgtctcgagttgc | 60 |
| r: | tcaaaggggtttccgtgtag | |||
| Toll-like receptor 9 (human) - NM_017442.3 | hTLR-9 | f: | cctattcatggacggca.act | 60 |
| r: | gagtgacaggtgggtgaggt | |||
| Myeloid Differentiation Primary Response Gene 88 (human) - NM 001172567.1 | hMyD88 | f: | tgcagagcaaggaatgtgac | 60 |
| r: | aggatgctggggaactcttt | |||
| Interferon Regulatory Factor 3 (human) - NM 001571.5 | hIRF-3 | f: | qaggtgacagccttctaccg | 60 |
| r: | tgcctcacgtagctcatcac | |||
| Interferon Regulatory Factor 7 (human) - NM 001572.3 | hIRF-7 | f: | taccatctacctgggcttcg | 60 |
| r: | gctccataaggaagcactcg | |||
| Melanoma Differentiation-Associated Gene 5 (human) - NM_020746.4 | hMda-5 | f: | ggggcatggagaataactca | 60 |
| r: | tgcccatgttgctgttatgt | |||
| NACHT, LRR and PYD Domains-Containing Protein 3 (human) - NM 004895.4 | hNALP3 | f: | cttctctgatgaggcccaag | 60 |
| r: | gcagcaaactggaaaggaag | |||
| Retinoic Acid inducible Gene l(human) - NM 014314.3 | hRIG-I | f: | gcaacagtgcagaggtgaaa | 60 |
| r: | caaaagagcatccagcaaca | |||
| Interferon α (murin) - NM_010502.2 | mIFN-α | f: | tcaatgacctgcaagctgtc | 62 |
| r: | agcaattggcagaggaagac | |||
| Interferon β (murin) - NM_010510.1 | mIFN-β | f: | ccctatggagatgacggaga | 60 |
| r: | ctgtctgctggtggagttca | |||
| Interleukin 1α (murin) - NM_010554.4 | mIL-1α | f: | gcaacgggaagattctgaag | 62 |
| r: | tgacaaacttctgcctgacg | |||
| Interleukin 6 (murin) - NM_031168.1 | mIL 6 | f: | ccggagaggagacttcacag | 60 |
| r: | tccacgatttcccagagaac | |||
| Tumor necrosis factor α (murin) - NM_013693.2 | mTNFα | f: | ccgatgggttgtaccttgtc | 60 |
| r: | cggactccgcaaagtctaag | |||
| 18S ribosomal RNA (murin) - NR_003278.3 | m18S | f: | cgcggttctattttgttggt | 60 |
| r: | agtcggcatcgtttatggtc | |||
| Green Fluorescent Protein - L29346.1 | GFP | f: | acgtaaacggccacaagttc | 60 |
| r: | aagtcgtgctgcttcatgtg | |||
| DNA- Dependent Activator of Interferon- Regulatory Factors (human) - NM 030776.2 | hDAI | f: | aaag catggacgattta ccg | 60 |
| r: | atgatgttcccgtgtccaat | |||
| Interferon, gamma- inducible Protein 16 (human) - NM 001206567.1 | hIFI16 | f: | gctgaccgaaacatggagat | 60 |
| r: | cagatctcaactccccggta | |||
| Interleukin 1β (human) - NM_000576.2 | hIL-1β | f: | ttcgacacatgggataacga | 60 |
| r: | tctttcaacacgcaggacag | |||
| TIR- Domain-containing Adapter-inducing Interferon-β (human) - AB093555.1 | hTRIF | f: | caggagcctgaggagatgag | 60 |
| r: | ctgggtagttggtgctggtt | |||
| Interferon-beta Promoter Stimulator 1 (human) - AB232371.1 | hIPS-1 | f: | ataagtccgagggcaccttt | 60 |
| r: | gtgactaccagcacccctgt | |||
| Abscent In Melanoma 2(human) - NM_004833.1 | hAM2 | f: | gctgcaccaaaagtctctcc | 60 |
| r: | tcaaacgtgaagggcttctt | |||
| Caspase-l (human) - NM_033292.3 | hCASP-1 | f: | gaaggcatttgtgggaagaa | 60 |
| r: | ggtgtggaagagcagaaagc |
Figure 1Cutaneous adenoviral gene delivery. (A) Baseline expression of cytokines and potentially in cytoplasmatic nucleic acid recognition involved receptors or adapter molecules in HaCaT cells and primary human keratinocytes (HKC). Data was generated via qRT-PCR and is displayed as mRNA concentration in ng/g 18S rRNA (* = p < 0,05; ** = p < 0,005). (B) Comparative efficiency of adenoviral vectors in HaCaT cells amd HKC. Quantitative analysis of GFP-positive cells 48 hours after transfection or transduction of HaCaT cells and HKC with 5 μg adenoviral DNA (AdDNA[5μg]) or 1.1 × 109 IU (AdV[0,5μg]) and 1.1 × 1010 IU (AdV[5μg]) adenoviral vectors (* = p < 0,05; ** = p < 0,005). (C) Comparative GFP expression in HaCaT cells and HKC. The specific transcript was determined 48 h after transfection with 5 μg/ml medium of isolated adenoviral DNA (AdDNA[5μg]) and compared to transduction with 1.1 × 109 IU (AdV[0,5μg]) and 1.1 × 1010 IU (AdV[5μg]) of a GFP-encoding adenoviral vector (* = p < 0,05; ** = p < 0,005). (D) Comparative type-I-interferon expression in HaCaT cells and HKC. The specific transcript was determined 6 h after transfection with 5 μg/ml medium of isolated adenoviral DNA (AdDNA[5μg]) and compared to transduction with 1.1 × 109 IU (AdV[0,5μg]) and 1.1 × 1010 IU (AdV[5μg]) of a GFP-encoding adenoviral vector (* = p < 0,05; ** = p < 0,005). (E) Comparative cytokine expression after transfection of HaCaT cells and HKC with 5 μg/ml isolated adenoviral DNA for 15 h (HaCaT) or 6 h (HKC). These time points were determined (maximum expression) by a time course of cytokine expression in hacats in a previous study by Steinstraesser et al. ( Steinstraesser et al. 2011 ). Study groups included n = 18 (type-I-IFN) or n = 6 (cytokines) samples. Data was normalized to a vehicle control (* = p < 0,05; ** = p < 0,005).
Figure 2Immune reaction after cutaneous adenoviral gene delivery. (A) Transduction control of a Bo-Drum®. Representative exposition of a Bo-Drum® 48 h after transduction of fixed skin sample with 1 × 1010 IU GFP-encoding adenoviral vector (Ad-GFP) (1: transmitted light image; 2: fluorescent image; 3: overlay). (B) Kinetics of cytokine expression after Bo-Drum® transduction. Time course (3 - 96 h) of cytokine mRNA expression (x-fold in relation to a vehicle control) after ex vivo transduction of human full skin in relation to a vehicle control (PBS injection). Per timepoint, n = 6 samples (from two different patients) were transduced with 1 × 1010 IU Ad-GFP (* = p < 0,05; ** = p < 0,005). (C) Adenovirus induced immune reaction in vivo. GFP-fluorescence detection of immunocompetent, hairless mice (SKH-1h/r) at timepoints of 7–42 days after intradermal injection (white arrow) of 1010 IU Ad-GFP (n = 3 per group). An additional vector application and reapplication of the same vector doses was performed on day 14 and 28 (* = p < 0.05, ** = p < 0.005). (D) Type-I-interferon and cytokine expression in vivo. RT-PCR analysis of type-I-interferon and cytokine expression at timepoints of 1, 6, 24, 48, 72 and 120 h after first application (PBS + AdV) and reapplication (AdV + AdV) of 1010 IU Ad-GFP (* = p < 0.05, # = p < 0.005; AdV + AdV) of 1010 IU Ad-GFP in immunocompetent (SKH-1h/r) (A) and athymic (Foxn-1nu) (B) mice. Data was presented as mean ± SEM (n = 3 per group/timepoint).
Figure 3Inhibition of signaling cascades. Cytokine expression after transfection of HaCaT cells and HKC with 5 μg/ml of adenoviral DNA with a follow-up of 15 h (HaCaT) or 6 h (HKC). One hour before transfection, inhibitors of indicated signaling molecules were added to the cell culture medium (10 mM final concentration). Data is indicated as percentage expression of cytokines in relation to a non-inhibited positive control (* = p <0.05, ** = p <0.005).
Figure 4Induction of innate immune signalling cascades. Induction of Toll-like receptors (TLR), Inflammasome-building components (Inf), RIG-like receptors (RLR), Interferon-regulatory factors (IRF) and DAI expression (x-fold in relation to a vehicle control) 15 h (HaCaT) or 6 h (HKC) after transfection of HaCaT cells and HKC with 5 μg/ml of adenoviral DNA (* = p <0.05, ** = p <0.005).
Figure 5siRNA-mediated inhibition of gene expression. (A) Efficiency of siRNA - mediated inhibition of gene expression. Expression of AIM2, NALP3, mda5 and DAI mRNA in HaCaT cells and HKC 48 h after siRNA transfection (* = p <0.05, ** = p <0.005). (B) Effects of siRNA - mediated inhibition of potential receptor gene expression. Expression of type-I-interferon (x-fold in relation to a vehicle control) after siRNA-mediated inhibition of potential DNA receptor mRNA expression. Two days after silencing, cells were transfected with 5 μg/ml isolated adenoviral DNA for 15 h (HaCaT) or 6 h (HKC) (* = p <0.05).
Normalized data of type-I-interferon expression after siRNA - mediated inhibition of gene expression of potential DNA receptors in HaCaT cells and HKC ([siRNA - Efficiency (Expression in % of control)/type-I-IFN expression (Expression in % of control)] ± SEM)
| AIM2 | NALP3 | mda5 | DAI | |||||
|---|---|---|---|---|---|---|---|---|
| 0,79± | 0,75± | 1,29± | 0,88± | 0,81± | 0,71± | 1,14± | 0,92± | |
| 0,15 | 0,12 | 0,12 | 0,15 | 0,07 | 0,03 | 0,04 | 0,11 | |
| 0,98± | 1,27± | 0,72± | 0,70± | 0,60± | 0,82± | 1,07± | 0,83± | |
| 0,02 | 0,65 | 0,01 | 0,07 | 0,03 | 0,3 | 0,09 | 0,03 | |
Figure 6Transgene expression after siRNA-mediated gene expression of AIM2, NALP3, mda5 and DAI. Quantitative (A) and qualitative (B) representation of the GFP expression in HaCaT cells 48 h after siRNA - mediated inhibition of AIM2, NALP3, mda5 and DAI and subsequent transduction with 1 × 108 IU Ad5-GFP or PBS (control) (* = p < 0.05; ** = p < 0.005).